文献速递前列腺癌

血液基因表达特征与mCRPC患者对阿比特龙联合泼尼松或恩扎卢胺的应答相关

Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-10-02

研究利用51例接受阿比特龙联合泼尼松或恩扎卢胺治疗的转移性去势抵抗性前列腺癌(mCRPC)患者的基线血样,进行循环肿瘤细胞(CTC)计数和141个基因/异构体的qPCR表达分析。基于8个基因的表达特征在测试集中对总生存(OS)的c-index为0.87(95%CI [0.80, 0.94]),低风险与高风险组中位OS分别为未达到与18个月(HR 5.32 [1.91-14.80], p=0.001)。若经更大规模前瞻性研究验证,该检测可能预测最可能从第二代抗雄治疗中获益的患者。

要点

  • 基线血液8基因表达特征与mCRPC患者OS强相关,c-index 0.87。
  • 低风险组中位OS未达到,高风险组为18个月(HR 5.32, p=0.001)。
  • 该特征对OS的关联强于临床变量或CTC计数单独或联合。

核心结论

  • 基线血液8基因表达特征与接受阿比特龙联合泼尼松或恩扎卢胺治疗的mCRPC患者的总生存显著相关。

研究设计与样本

  • 前瞻性收集51例开始阿比特龙或恩扎卢胺治疗的mCRPC男性基线血样,进行CTC计数和qPCR基因表达分析。
  • 队列随机分为训练集(n=37)和测试集(n=14)。

主要发现

  • 与OS最相关的基因包括MSLN、ARG2、FGF8、KLK3、ESRP2、NPR3、CCND1和WNT5A。
  • 测试集中8基因特征的c-index为0.87(95%CI [0.80, 0.94])。
  • 低风险 vs 高风险基因表达特征患者的中位OS分别为未达到 vs 18个月(HR 5.32 [1.91-14.80], p=0.001)。
  • 在41例有PFS数据的患者中,低风险 vs 高风险组中位PFS分别为20 vs 5个月(HR 2.95 [1.46-5.98], p=0.003)。

临床怎么用

  • 若经更大规模前瞻性研究验证,该血液检测可能帮助筛选最可能从第二代抗雄治疗中获益的mCRPC患者。

局限性

  • 样本量较小(51例),需更大规模前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Precision medicine approaches for managing patients with metastatic castrate-resistant prostate cancer (mCRPC) are lacking. Non-invasive approaches for molecular monitoring of disease are urgently needed, especially for patients suffering from bone metastases for whom tissue biopsy is challenging. Here we utilized baseline blood samples to identify mCRPC patients most likely to benefit from abiraterone plus prednisone (AAP) or enzalutamide. METHODS: Baseline blood samples were collected for circulating tumor cell (CTC) enumeration and qPCR-based gene expression analysis from 51 men with mCRPC beginning treatment with abiraterone or enzalutamide. RESULTS: Of 51 patients (median age 68 years [51-82]), 22 received AAP (abiraterone 1000 mg/day plus prednisone 10 mg/day) and 29 received enzalutamide (160 mg/day). The cohort was randomly divided into training (n = 37) and test (n = 14) sets. Baseline clinical variables (Gleason score, PSA, testosterone, and hemoglobin), CTC count, and qPCR-based gene expression data for 141 genes/isoforms in CTC-enriched blood were analyzed with respect to overall survival (OS). Genes with expression most associated with OS included MSLN, ARG2, FGF8, KLK3, ESRP2, NPR3, CCND1, and WNT5A. Using a Cox-elastic net model for our test set, the 8-gene expression signature had a c-index of 0.87 (95% CI [0.80, 0.94]) and was more strongly associated with OS than clinical variables or CTC count alone, or a combination of the three variables. For patients with a low-risk vs. high-risk gene expression signature, median OS was not reached vs. 18 months, respectively (HR 5.32 [1.91-14.80], p = 0.001). For the subset of 41 patients for whom progression-free survival (PFS) data was available, the median PFS for patients with a low-risk vs high-risk gene expression signature was 20 vs. 5 months, respectively (HR 2.95 [1.46-5.98], p = 0.003). CONCLUSIONS: If validated in a larger prospective study, this test may predict patients most likely to benefit from second-generation antiandrogen therapy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Haas NB, LaRiviere MJ, Buckingham TH, et al. Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Prostate Cancer Prostatic Dis. 2020. PMID: 33009489. doi:10.1038/s41391-020-00295-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。